POTENCIAIS EFEITOS ADVERSOS E INTERAÇOES FARMACOLOGICAS DO ALISCIRENO





POTENCIAIS EFEITOS ADVERSOS E INTERAÇOES FARMACOLOGICAS DO ALISCIRENO

(especial para SIIC © Derechos reservados)
O aliscireno está associado a diversos efeitos adversos, sendo os mais frequentes as cefaleias e a diarreia. Outros efeitos adversos descritos são nasofaringite, hipercalémia e cálculos renais. Relativamente à existência de interações, foi demonstrado que o paracetamol afeta a eficácia do aliscireno provocando um aumento nos valores da tensão arterial sistólica e diastólica. O sumo de toranja afeta a farmacocinética do aliscireno diminuindo a sua eficácia, estando contra-indicada esta associação.
Autor:
Manuel Morgado
Columnista Experta de SIIC

Institución:
Centro Hospitalar Cova da Beira


Artículos publicados por Manuel Morgado
Coautor
Daniela Marques* 
Farmaceutico, Farmácia Comunitária Sousa, Portugal*
Recepción del artículo
8 de Septiembre, 2015
Aprobación
9 de Junio, 2016
Primera edición
6 de Julio, 2016
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Introdução Aliscireno é um fármaco anti-hipertensor que atua por inibição da renina. A sua introdução na União Europeia é relativamente recente, remontando ao ano de 2007. Devido à introdução relativamente recente deste princípio ativo na prática clínica torna-se pertinente rever a informação, publicada nos últimos anos, relacionada com a segurança da sua utilização em farmacoterapia.  Objetivo Rever os potenciais efeitos adversos e interações envolvendo o aliscireno, relatados após a sua introdução no mercado farmacêutico. Métodos Revisão bibliográfica através da pesquisa e análise de artigos publicados na base de dados PubMed, pela interseção dos termos “aliskiren interactions” e “aliskiren adverse effects”. Os sites “PRAC- Pharmacovigilance Risk Assessment Agency” (Agência Europeia do Medicamento) e “OSE-Office of Surveillance and Epidemiology” (Food and Drug Administration) também foram consultados.  Resultados O efeito adverso mais comum do aliscireno é a diarreia, mas o rash, angioedema, tonturas e problemas renais também podem ocorrer. O aliscireno interage com o paracetamol e com o sumo de toranja ficando alterada a sua farmacocinética e farmacodinâmica. Conclusão O aliscireno foi recentemente introduzido no mercado farmacêutico e a informação disponível sobre os seus efeitos adversos e interações farmacológicas é escassa e encontra-se dispersa. O farmacêutico desempenha um papel muito importante no desenvolvimento de estratégias tendo em vista a prevenção a e minimização dos efeitos adversos e interações farmacológicas relacionados com o aliscireno.     

Palabras clave
aliscireno, aliscireno, efeitos adversos, efectos adversos, interações, interacciones, anti-hipertensor, anti-hipertensor, revisão, revisión, inhibidor de la renina, inibidor da renina


Artículo completo

(castellano)
Extensión:  +/-5.44 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Introduction: Aliskiren is a drug used for the treatment of hypertension, and it acts by inhibition of the renin enzyme. The introduction of this antihypertensive in the European Union is relatively recent, it dates back to 2007. Due to the relatively recent introduction of this active ingredient in clinical practice, it becomes relevant to review the information published in recent years related to the safety of their use in pharmacotherapy. Aim: To review the potential adverse effects and drug interactions involving the antihypertensive drug aliskiren. Methods: Literature review through research and analysis of articles published at PubMe" and other databases such as Scopus and Web of Science, Thomson Reuters. The websites of Pharmacovigilance Risk Assesment Agency (European Medicines Agency) and Office of Surveillance and Epidemiology (Food and Drug Administration) were also be analyzed. Results: The most common adverse effect of aliskiren is diarrhea but rash, angioedema, dizziness and renal problems have also been reported. Acetaminophen and grapefruit juice were reported to interact with this antihypertensive drug modifying its pharmacokinetics and pharmacodynamics. Conclusion: Aliskiren was recently introduced in the pharmaceutical market and the information available about its adverse effects and drug interactions are scarce and dispersed. The pharmacist has a very important role in developing strategies aimed at prevention and minimization of adverse effects and drug interactions of aliskiren.

Key words
aliskiren, side effects, interactions, resivion, revision, renin inhibitor


Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Cardiología, Farmacología
Relacionadas: Atención Primaria, Farmacología, Geriatría, Medicina Farmacéutica, Toxicología



Comprar este artículo
Extensión: 5.44 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Manuel Morgado, 6200-506, Quinta do Alvito, Covilhã, Portugal
Bibliografía del artículo
1. Liu Y, Yan R, Song A, Niu X, Cao C, Wei J, et al. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy. Am J Hypertens 27(2):268-78, 2014.
2. Escobar C, Barrios V. An evaluation of the latest evidence relating to renin-angiotensin system inhibitors. Expert Opin Drug Metab Toxicol 9(7):847-58, 2013.
3. Taylor AA, Ragbir S. Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension. Patient Prefer Adherence 6:555-63, 2012.
4. Volman S, Benitez F, Cedenio H, Giorgi M, Jaramillo N, Molina N, et al. Use of aliskiren in Latin America in a real-world setting: aliskiren in Latin America Study (ALAS). Ther Adv Cardiovasc Dis 7(4):189-96, 2013.
5. Balcarek J, Sevá PB, Bryson C, Azizi M, Ménard J, Garrelds I, et al. Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension 63(5):942-50, 2014.
6. Sullivan J, Keefe D, Zhou Y, Satlin L, Fang H, Yan J. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clin Pediatr (Phila) 52(7):599-607, 2013.
7. St Peter W, Odum L, Whaley-Connell A. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. Pharmacotherapy 33(5):496-514, 2013.
8. Fogari R, Mugellini A, Zoppi A, Preti P, Maffioli P, Perrone T, et al. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. Expert Opin Pharmacother 14(4):371-84, 2013.
9. Lee K, Chan C, Yang Y, Hsieh Y, Huang Y, Lin H. Aliskiren attenuates chronic carbon tetrachloride-induced liver injury in mice. Eur J Clin Invest 42(12):1261-71, 2012.
10. Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Verdecchia P. Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opin Drug Saf 11(4):659-70, 2012.
11. Sadeghpour A, Rappolt M, Ntountaniotis D, Chatzigeorgiou P, Viras K, Megariotis G, et al. Comparative study of interactions of aliskiren and AT1 receptor antagonists with lipid bilayers. Biochim Biophys Acta 1848(4):984-94, 2015.
12. Uger T. The role of the renin-angiotensin system in the development of cardiovascular disease. The American Journal of Cardiology 89(2A), 2002.
13. Bonanni L, Dalla VM. Oral renin inhibitors in clinical practice: a perspective review. Ther Adv Chronic Dis 3(4):173-81, 2012.
14. Dhakarwal P, Agrawal V, Kumar A, Goli K, Agrawal V. Update on role of direct renin inhibitor in diabetic kidney disease. Ren Fail 36(6):963-9, 2014.
15. Saraswat M, Addepalli V, Jain M, Pawar V, Patel R. Renoprotective activity of aliskiren, a renin inhibitor in cyclosporine A induced hypertensive nephropathy in dTG mice. Pharmacol Rep 66(1):62-7, 2014.
16. Riccioni G. The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient. The Adv Endocrinol Metab 4(5):139-145, 2013.
17. Hoffmann P, Beckman D, McLean L, Yan J. Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression. Toxicol Appl Pharmacol 275(1):36-43, 2014.
18. Khadzhynov D, Slowinski T, Lieker I, Neumayer H, Albrecht D, Streefkerk H, et al. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis. Clin Pharmacokinet 51(10):661-9, 2012.
19. Tocci G, Aimo G, Caputo D, De Matteis C, Di Napoli T, Granatelli A, et al. An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy. High Blood Press Cardiovasc Prev 19(2):73-83, 2012.
20. Liu Y, Chen K, Kou X, Han Y, Zhou L, Zeng C. Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. PLoS One 8(7), 2013.
21. Szeto C, Kwan B, Chow K, Leung C, Li P. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy: a randomized cross-over study. PLoS One 8(5), 2013.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618